| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73891 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
82 |
kx |
2024-12-19 |
| 73892 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
83 |
h |
2024-12-19 |
| 73893 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
100 |
WYQ |
2024-12-19 |
| 73894 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
117 |
zyl |
2024-12-19 |
| 73895 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
103 |
kx |
2024-12-19 |
| 73896 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
103 |
wyh |
2024-12-19 |
| 73897 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
73 |
h |
2024-12-19 |
| 73898 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
88 |
h |
2024-12-19 |
| 73899 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
111 |
wyh |
2024-12-19 |
| 73900 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
87 |
h |
2024-12-19 |
| 73901 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
117 |
WYQ |
2024-12-19 |
| 73902 |
1626359-62-3，SPDB-DM4， ADC试剂 |
74 |
kx |
2024-12-19 |
| 73903 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
81 |
WYQ |
2024-12-19 |
| 73904 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
102 |
wyh |
2024-12-19 |
| 73905 |
DOTA-(D)Phe(1)-Tyr(3) |
77 |
h |
2024-12-19 |
| 73906 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
118 |
zyl |
2024-12-19 |
| 73907 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
115 |
WYQ |
2024-12-19 |
| 73908 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
75 |
h |
2024-12-19 |
| 73909 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
87 |
WYQ |
2024-12-19 |
| 73910 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
102 |
wyh |
2024-12-19 |
| 73911 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
128 |
WYQ |
2024-12-19 |
| 73912 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
157 |
kx |
2024-12-19 |
| 73913 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
80 |
h |
2024-12-19 |
| 73914 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
87 |
wyh |
2024-12-19 |
| 73915 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
110 |
zyl |
2024-12-19 |
| 73916 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
133 |
WYQ |
2024-12-19 |
| 73917 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
90 |
kx |
2024-12-19 |
| 73918 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
99 |
h |
2024-12-19 |
| 73919 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
87 |
WYQ |
2024-12-19 |
| 73920 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
65 |
wyh |
2024-12-19 |
| 73921 |
cas:330970-70-2 Alloc-Val-Ala-OH |
83 |
zyl |
2024-12-19 |
| 73922 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
68 |
h |
2024-12-19 |
| 73923 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
69 |
WYQ |
2024-12-19 |
| 73924 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
111 |
kx |
2024-12-19 |
| 73925 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
79 |
WYQ |
2024-12-19 |
| 73926 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
166 |
kx |
2024-12-19 |
| 73927 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
112 |
WYQ |
2024-12-19 |
| 73928 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
108 |
h |
2024-12-19 |
| 73929 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
97 |
zyl |
2024-12-19 |
| 73930 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
81 |
WYQ |
2024-12-19 |
| 73931 |
Boc-Val-Cit CAS:870487-08-4 |
96 |
zyl |
2024-12-19 |
| 73932 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
104 |
h |
2024-12-19 |
| 73933 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
60 |
kx |
2024-12-19 |
| 73934 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
97 |
h |
2024-12-19 |
| 73935 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
80 |
kx |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询